Tardive dyskinesia

Tardive dyskinesia
Other namesLinguofacial dyskinesia, tardive dystonia, tardive oral dyskinesia
Tardive dyskinesia is believed to involve the neurotransmitter dopamine.
Pronunciation
  • /ˈtɑːrdɪv ˌdɪskɪˈnʒə/, /tɑːrdv/ /ˌdɪskəˈnʒə/
SpecialtyNeurology, psychiatry
SymptomsInvoluntary, repetitive body movements
CausesNeuroleptic medications (antipsychotics), metoclopramide
Diagnostic methodBased on symptoms after ruling out other potential causes
Differential diagnosisHuntington's disease, cerebral palsy, Tourette syndrome, dystonia
PreventionUsing lowest possible dose of neuroleptic medication
TreatmentStopping neuroleptic medication if possible, switching to clozapine
MedicationValbenazine, tetrabenazine, botulinum toxin
PrognosisVariable
Frequency20% (atypical antipsychotics)
30% (typical antipsychotics)

Tardive dyskinesia (TD) is an iatrogenic disorder that results in involuntary repetitive body movements, which may include grimacing, sticking out the tongue or smacking the lips, which occurs following treatment with medication. Additional motor symptoms include chorea or athetosis. In about 20% of people with TD, the disorder interferes with daily functioning. If TD is present in the setting of a long-term drug therapy, reversibility can be determined primarily by severity of symptoms and how long symptoms have been present before the long-term drug has been stopped.

Tardive dyskinesia occurs as a result of long-term use of dopamine-receptor-blocking medications such as antipsychotics and metoclopramide. These medications are usually used for mental illness but may also be given for gastrointestinal or neurological problems. The condition typically develops only after months to years of use. The diagnosis is based on the symptoms after ruling out other potential causes.

Efforts to prevent the condition include either using the lowest possible dose or discontinuing use of antipsychotics. Treatment includes stopping the antipsychotic medication if possible (although this may temporarily worsen symptoms) or switching to clozapine. Other medications such as valbenazine, tetrabenazine, or botulinum toxin may be used to lessen the symptoms. With treatment, some see a resolution of symptoms, while others do not.

Rates in those on atypical antipsychotics are about 20%, while those on typical antipsychotics have rates of about 30%. The risk of acquiring the condition is greater in older people, for women, as well as patients with mood disorders and/or medical diagnoses receiving antipsychotic medications. The term tardive dyskinesia first came into use in 1964.